GLP-3R — The Next-Generation Triple Agonist

The Triple-Pathway Leap

GLP-3R represents a notable evolution in incretin research by engaging three receptors: GLP-1, GIP, and glucagon. The inclusion of glucagon receptor activity introduces an energy expenditure dimension that complements satiety and glucose-related pathways.

Mechanistic Overview

GLP-1: Investigated for appetite regulation, gastric emptying, and glucose-dependent insulin activity.

GIP: Explored as a complementary incretin pathway with potential additive effects.

Glucagon: Studied for roles in fat metabolism and caloric burn, adding depth to body composition research.

Why GLP-3R Attracts Interest

The triple mechanism allows researchers to evaluate how reduced intake signals (GLP-1/GIP) and increased expenditure signals (glucagon) may interact. This integrated approach is of growing interest for studies centered on energy balance and body composition.

Example Endpoints

Appetite & Satiety metrics

Gastric kinetics proxies

Glucose tolerance in controlled models

Indirect calorimetry for expenditure

Body composition measures (e.g., fat mass, lean mass)

Our GLP-3R is provided in research-configured vial sizes with Research Use Only labeling and batch-level quality documentation to support reproducibility.

COMPLIANCE NOTICE: For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. The information provided summarizes published research and is not medical advice. No statements herein have been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.